Announced Thu, 9 Jul · 08:41 IST
Biocon Yesafili biosimilar clinical data published in two journals
Compliance View source PDF
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+5.2%1-day move
₹397.55
prior close
₹399.80
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1+0.3+1.4+1.5+5.2+3.8+9.9+9.3+11.2+9.7————
Up moveDown movePending
AI summary
Biocon announced publication of two peer-reviewed studies supporting Yesafili, its aflibercept biosimilar for diabetic macular edema. Phase III INSIGHT trial showed comparable safety and efficacy between MYL-1701P and reference aflibercept, including for patients who switched. Published in British Journal of Ophthalmology and Expert Opinion on Biological Therapy. Yesafili was US FDA approved in May 2024, with US launch upcoming.
Likely market impact
Positive clinical evidence supports upcoming US launch of Yesafili, strengthening Biocon biosimilar portfolio and growth outlook.